Nsclc Trials in New York, United States
Conditions / Nsclc / New York, United States
Nsclc is a medical condition with active clinical research programs worldwide.
56 total trials for this combination
Showing top 10 of 56 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | TERMINATED | PHASE1 |
| NCT04672460 | A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | RECRUITING | PHASE1/PHASE2 |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) | COMPLETED | PHASE1/PHASE2 |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | UNKNOWN | PHASE1 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | TERMINATED | PHASE2 |
| NCT04981119 | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | RECRUITING | — |